PAVmed Inc (PAVM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PAVmed Inc (PAVM) has a cash flow conversion efficiency ratio of -0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-896.00K) by net assets ($25.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is PAVmed Inc's balance sheet to measure how much of total assets are equity-financed.
PAVmed Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how PAVmed Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PAVM cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
PAVmed Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PAVmed Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
21st Century Management Services Limited
NSE:21STCENMGM
|
-0.595x |
|
C&C Group plc
LSE:CCR
|
0.072x |
|
Fidelity Asian Values
LSE:FAS
|
0.000x |
|
Lucapa Diamond Company Ltd
AU:LOM
|
-0.039x |
|
Hensel Davest Indonesia Tbk PT
JK:HDIT
|
-0.001x |
|
Connexa Sports Technologies Inc.
NASDAQ:YYAI
|
-0.186x |
|
China Natural Resources Inc
NASDAQ:CHNR
|
-0.019x |
|
BIRD RIVER RES. INC.
F:1Q1A
|
N/A |
Annual Cash Flow Conversion Efficiency for PAVmed Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of PAVmed Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see PAVmed Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.03 Million | $-33.55 Million | 4.771x | +120.21% |
| 2023-12-31 | $-24.02 Million | $-52.04 Million | 2.167x | +133.37% |
| 2022-12-31 | $10.93 Million | $-70.98 Million | -6.492x | -1170.21% |
| 2021-12-31 | $79.42 Million | $-40.59 Million | -0.511x | -101.10% |
| 2020-12-31 | $-473.00K | $-21.91 Million | 46.330x | +1508.74% |
| 2019-12-31 | $-4.64 Million | $-13.36 Million | 2.880x | -18.85% |
| 2018-12-31 | $-2.48 Million | $-8.79 Million | 3.549x | +52.97% |
| 2017-12-31 | $-2.85 Million | $-6.61 Million | 2.320x | -83.38% |
| 2016-12-31 | $-319.07K | $-4.45 Million | 13.962x | +808.29% |
| 2015-12-31 | $633.92K | $-1.25 Million | -1.971x | -2499.63% |
| 2014-12-31 | $794.83K | $-60.27K | -0.076x | -- |
About PAVmed Inc
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing… Read more